We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fast track to MS drug.
- Authors
Sheridan, Cormac
- Abstract
The article is about the launch of the humanized monoclonal antibody Antegren, developed by Biogen Idec Inc. and Elan Corp. as a treatment for multiple sclerosis (MS) and its effect in the market. MS has ben viewed as a chronic autoimmune disease, caused by inflammatory T-helper cells infiltrating the central nervous system and attacking the myelin sheat, a fatty-protein complex deposited in concentric layers around nerve cell axons. Over the past decade, MS patients and their treating physicians have had essentially two alternatives, β-interferon and Copaxone, a mixture of peptides that mimics the structure of myelin basic protein, a constituent of myelin.
- Subjects
MULTIPLE sclerosis treatment; BIOGEN Inc. (2003- ); ELAN Corp. PLC; NEUROSCIENCES; THERAPEUTICS; CLINICAL medicine
- Publication
Nature Biotechnology, 2004, Vol 22, Issue 8, p939
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0804-939